Kinnate BiopharmaÂ Inc (KNTE) Financials

$2.65

$0.00 (0.00%)

As on 03-Apr-2024 16:00EDT

Market cap

$125 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.80	0.60	0.12	0.08	--	--
Gross Profit	-0.80	-0.60	-0.12	-0.08	--	--
Operating Expenses	118.21	118.52	90.11	36.00	12.01	7.63
Operating Profit (EBIT)	-119.01	-118.52	-90.11	-36.00	-12.01	-7.63
Other Income	--	2.25	0.35	--	--	--
Profit before Tax	-112.65	-116.27	-89.76	-35.76	-11.97	-7.63
Provision for Tax	--	-2.25	-0.35	-0.33	-0.04	--
Profit after Tax (Net Income)	-112.65	-114.02	-89.42	-35.43	-11.93	-7.63
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	-116.27	-89.76	-35.76	-9.94	-7.63

Liabilities ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	159.33	223.47	319.48	393.27	-17.49	7.61
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	2.28	3.19	35.00	3.94	93.15	--
Current Liabilities	12.00	17.17	12.39	7.30	1.95	0.47
Total Liabilities	173.61	278.83	366.86	400.57	77.61	8.08

Assets ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	15.43	47.99	108.17	0.37	0.15	--
Current Assets	158.18	230.84	258.69	400.20	77.45	8.08
Total Assets	173.61	278.83	366.86	400.57	77.61	8.08
Total Debt*	3.18	4.18	--	--	--	--
Net Current Assets	146.18	213.67	246.30	392.90	75.51	7.61

Cashflow ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	-100.04	-89.03	-71.07	-30.18	-10.53	-8.20
Cash Flow from Investing Activities	--	-6.83	-180.57	-31.71	-31.71	-31.71
Cash from Financing Activities	1.33	1.16	36.24	350.90	79.98	15.20
Net Cash Inflow / Outflow	--	-94.70	-215.40	--	--	--

Financials Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-2.40	-2.59	-2.03	-5.06	--	--
Cash EPS ($)	-2.38	-2.58	-2.03	-5.05	--	--
Adjusted Book Value ($)	3.39	5.08	7.26	56.18	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	-2.13	-2.02	-1.62	-4.31	--	--
Free Cash Flow per Share ($)	-2.13	-2.09	-1.63	-4.35	--	--

Profitability Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	-57.75	-41.68	-25.09	-18.86	241.51	--
ROE (%)	-58.86	-42.00	-25.09	-18.86	241.51	--
ROA (%)	-49.80	-35.32	-23.30	-14.82	-27.84	--
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	-5,067.60	-25,693.97	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-0.41	-31.53	-150.30	-199.71	-57.43	--
Net Profit Growth (%)	1.20	-27.52	-152.35	-197.11	-56.30	--
EPS Growth (%)	0.08	-0.28	0.60	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	-0.99	-2.35	-8.72	-7.86	--	--
Price / Book Value	0.70	1.20	2.44	0.71	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.33	-0.60	-6.23	3.30	--	--
Close Price ($)	2.37	6.10	17.72	39.78	--	--
High Price ($)	8.17	18.69	41.00	48.75	--	--
Low Price ($)	1.04	5.17	15.89	34.14	--	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	0.02	0.02	--	--	--	--
Short term debt to equity ratio	0.01	0.00	--	--	--	--
Current Ratio	13.19	13.45	20.88	54.79	39.82	17.30
Quick Ratio	--	--	--	--	--	--
Interest Coverage	--	-52.68	-258.94	-146.94	--	--

Operating Efficiency Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	1,143.06	1,849.83	10,523.95	10,772.67	--	--
Cash Conversion Cycle	--	--	--	--	--	--